Resolution based on the results of Council meetings on the topic “Current problems in the treatment of nasopharyngeal cancer”

1. Chuprik-Malinovskaya T.P. Nasopharyngeal cancer. Аvailable at: https://rosoncoweb.ru/library/congress/ru/05/03.php (in Russ.).

2. Malignant neoplasms in Russia in 2022 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova, I.V. Lisichnikova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. 275 p. (in Russ.).

3. Absolute numbers, incidence, Both sexes, in 2022. Nasopharynx. The Global Cancer Observatory (GCO). Аvailable at: https://gco.iarc.fr/today/en/dataviz/pie?mode=population&group_populations=0&cancers=4

4. Yang Y., Qu S., Li J. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN 1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22(8):1162–74. DOI: 10.1016/S1470-2045(21)00302-8

5. Nasopharyngeal cancer. Clinical recommendations. 2020. Аvailable at: https://cr.minzdrav.gov.ru/recomend/535 (in Russ.).

6. Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical recommendations for the treatment of malignant tumors of the head and neck. Zlokachestvennye opukholi = Malignant tumors 2020;10(#3s2):93–108. (in Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-06

7. Nasopharyngeal cancer. Draft clinical guidelines. Association of Oncologists of Russia, 2024. Аvailable at: https://oncology-association.ru/clinical-guidelines-update (in Russ.).

8. Zhang L. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. Abstract 6000, ASCO 2021. Аvailable at : https://www.accc-cancer.org/docs/ossn-network/sc/meetings/scos-asco-direct-speaker-presentations/kaczmar-final-asco.pdf

9. Ding X., Zhang W.-J., You R. et al., Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. J Clin Oncol 2023;41:2571–82. DOI:/10.1200/JCO.22.01450